Summary & Overview

Other Infectious and Parasitic Diseases Diagnoses with MCC: Inpatient Reimbursement Overview

DRG 867 encompasses other infectious and parasitic disease diagnoses that include a Major Complication or Comorbidity, covering severe systemic infections and complex parasitic conditions requiring inpatient care. It matters for inpatient reimbursement because the presence of a Major Complication or Comorbidity elevates case severity and typically results in higher Medicare payment to reflect greater resource use.

Other Infectious and Parasitic Diseases Diagnoses with MCCDRG Other Infectious and Parasitic Diseases Diagnoses with MCCDRG 867Diagnosis-Related GroupInpatient ReimbursementMedicareInfectious DiseaseParasitologyHospital CodingAcute Care

DRG 867 Overview

DRG 867 covers hospitalizations for Other Infectious and Parasitic Diseases Diagnoses with Major Complication or Comorbidity, encompassing serious systemic infections and parasitic conditions that require intensive inpatient management. This Diagnosis-Related Group is significant for Medicare payment because cases with Major Complication or Comorbidity typically trigger higher reimbursement relative to less severe infectious disease DRGs, reflecting increased resource use, longer lengths of stay, and more complex care needs. Payers and hospital coders monitor assignment to this Diagnosis-Related Group to ensure accurate capture of clinical severity and payment. Accurate documentation of diagnoses that meet Major Complication or Comorbidity criteria is central to proper claim processing.

Clinical Trials

Acute inpatient antimicrobial optimization trials: randomized or pragmatic studies evaluating timing, spectrum, and route of antimicrobial therapy (including IV-to-oral switch strategies) for patients admitted with severe non-specific infectious and parasitic diseases plus major complications or comorbidities. These studies enroll heterogeneous inpatient populations with acute organ dysfunction, sepsis, or confirmed systemic infection where rapid source control and antimicrobial choice impact length of stay and organ support needs. Results inform hospital protocols for empiric therapy, stewardship metrics, and resource use that directly affect DRG-based reimbursement and utilization for this high-cost group.
Comparative effectiveness studies of adjunctive supportive interventions during index hospitalization: prospective cohort or randomized studies comparing different supportive care strategies (for example, escalation protocols for ICU transfer, criteria for advanced organ support, or bundled infection-management pathways) for patients with complex infectious/parasitic diagnoses and major complications. These trials focus on older adults and medically complex patients who are at high risk for prolonged hospitalization, readmission, and complications; they examine outcomes such as in-hospital mortality, ventilator- and vasopressor-free days, and total hospital costs. Findings guide clinical pathways and discharge planning practices that affect payer expenditures and DRG case-mix adjustment through changes in complication rates and resource intensity.
Post-discharge outcomes and readmission prevention research: longitudinal observational studies and interventional trials testing transitional care models, outpatient monitoring, or targeted rehabilitation for survivors of severe infectious/parasitic illnesses with major complications. These studies follow patients after discharge to measure functional recovery, infection recurrence, medication adherence, and 30- to 90-day readmission rates, often stratified by severity of index complications and social determinants of health. Evidence from this research supports strategies to reduce costly readmissions, optimize post-acute care placement, and refine bundled payment or population-health programs relevant to payers and health systems managing DRG 867 cases.

Related Codes

864-FEVER-AND-INFLAMMATORY-CONDITIONS

Fever and Inflammatory Conditions: Inpatient Reimbursement Overview

862-POSTOPERATIVE-AND-POST-TRAUMATIC-INFECTIONS-WITH-MCC

Postoperative and Post-Traumatic Infections with MCC: Inpatient Reimbursement Overview

870-SEPTICEMIA-OR-SEVERE-SEPSIS-WITH-MV-96-HOURS

Septicemia or Severe Sepsis with MV >96 Hours: Inpatient Reimbursement Overview

857-POSTOPERATIVE-OR-POST-TRAUMATIC-INFECTIONS-WITH-O-R-PROCEDURES-WITH-CC

Postoperative or Post-Traumatic Infections with O.R. Procedures with CC: Inpatient Reimbursement Overview

853-INFECTIOUS-AND-PARASITIC-DISEASES-WITH-O-R-PROCEDURES-WITH-MCC

Infectious and Parasitic Diseases with O.R. Procedures with MCC: Inpatient Reimbursement Overview

866-VIRAL-ILLNESS-WITHOUT-MCC

Viral Illness without MCC: Inpatient Reimbursement Overview

869-OTHER-INFECTIOUS-AND-PARASITIC-DISEASES-DIAGNOSES-WITHOUT-CC-MCC

Other Infectious and Parasitic Diseases Diagnoses without CC/MCC: Inpatient Reimbursement Overview

858-POSTOPERATIVE-OR-POST-TRAUMATIC-INFECTIONS-WITH-O-R-PROCEDURES-WITHOUT-CC-MCC

Postoperative or Post-Traumatic Infections with O.R. Procedures without CC/MCC: Inpatient Reimbursement Overview

872-SEPTICEMIA-OR-SEVERE-SEPSIS-WITHOUT-MV-96-HOURS-WITHOUT-MCC

Septicemia or Severe Sepsis without MV >96 Hours without MCC: Inpatient Reimbursement Overview

865-VIRAL-ILLNESS-WITH-MCC

Viral Illness with MCC: Inpatient Reimbursement Overview

Showing 1–10 of 16

Trek Health ingests and normalizes Transparency in Coverage data and payer policy updates to give provider organizations a clear view of how commercial reimbursement behaves across markets, payers, and services. Our platform transforms raw payer disclosures into structured intelligence that supports contract evaluation, payer negotiations, and service line strategy. By combining market benchmarks with ongoing policy visibility, Trek helps teams identify variability, risk, and opportunity in commercial reimbursement. The result is faster insight, stronger negotiating positions, and more informed financial decisions.